Neonatal herpes simplex virus infection.
These results suggest that Ara A, within its nontoxic dose range, may be efficacious in the treatment of neonatal HSV infection, provided the drug is given early in the course of the disease. Such studies as this have prompted a large scale multi-institutional study, which hopefully will provide a greater insight into the natural history of this usually devastating disease. The information gathered undoubtedly will lead to better and more specific antiviral agents as well as diagnostic techniques for earlier identification of neonatal HSV disease.